Alex Biese

The Food and Drug Administration approved Besponsa for pediatric patients aged 1 and older with relapsed or refractory CD22-positive, B-cell precursor ALL.

The Food and Drug Administration green lit a first-in-human phase 1 clinical study of Innocell, a vaccine for the treatment of stage 3 and 4 ovarian cancer.

Patients with small cell lung cancer have reasons to be optimistic these days, as one expert explains to CURE.

What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options?

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

The Food and Drug Administration has accepted a Biologics License Application for Tevimbra with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

“The biggest thing that I hate to see happen is that those conversations don't even happen [around cannabis and cancer],” said Dr. Brooke Worster.

Michelle Anderson-Benjamin, who received a diagnosis of metastatic breast cancer in 2022, works as a death doula to provide end-of-life support to patients and their families.

Patients with locally advanced penile squamous cell carcinoma who responded to neoadjuvant chemotherapy followed by consolidative lymphadenectomy experienced improved long-term survival outcomes.

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

“We've all been touched by breast cancer in some way. And we need everybody to be a part of this solution,” Kristen Dahlgren told CURE, regarding her decision to be a co-founder of the Cancer Vaccine Coalition.

Dr. Murugesan Manoharan of Miami Cancer Institute and Baptist Health South Florida shares key questions patients who have received a diagnosis of bladder cancer should ask their care team.

The Food and Drug Administration has approved a reduced dosing frequency of Tecvayli for patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for at least six months.

Personalized cancer vaccines are on the horizon and could be available for some patient populations as soon as next year, one expert said.

Last week, we saw FDA approvals for new drug regimens, as well as some expert opinion about cancer vaccines

A UCLA neurobiology professor and prostate cancer survivor discuss using artificial intelligence to map his disease and inform treatment decisions.

The Food and Drug Administration has approved Tagrisso plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

Treatment paradigms may soon be shifting in head and neck cancer, as recent research indicates that lower doses of chemoradiotherapy may be appropriate for some patients.

The Food and Drug Administration approved Tepmetko for adults with metastatic non-small cell lung cancer with MET exon 14 skipping alterations.

Moderna and Merck have initiated V940-001, a phase 3 study evaluating vaccine mRNA-4157 and anti-PD-1 therapy Keytruda as postsurgical treatment for stage 2B to 4 melanoma.

“Sleep apnea assessment must be a part of routine risk assessment for patients undergoing cancer therapeutics,” one researcher stated.

The Food and Drug Administration has approved Onivyde with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma, the agency has announced.

The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

From the San Francisco 49ers’ Trent Williams looking back on his cancer experience to a Republican congressman returning to work after myeloma treatment, here’s what’s happening in the oncology space this week.

Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.

Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when compared with those treated with Imfinzi or subject to observation.

The development of immune-related side effects is associated with improved overall survival among patients with metastatic non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitor therapy.

“We have to make it known to people that we are not just a patient,” said Michelle Anderson-Benjamin, CEO of the Fearless Warrior Project, who received a diagnosis of metastatic breast cancer in 2022.